01.12.2018 | Research article | Ausgabe 1/2018 Open Access

Conbercept for patients with age-related macular degeneration: a systematic review
- Zeitschrift:
- BMC Ophthalmology > Ausgabe 1/2018
Electronic supplementary material
Background
Methods
Literature searching
Eligibility criteria
Study selection and data extraction
Risk of Bias assessment
Statistical synthesis
Results
Search results and characteristics of included studies
Study ID | Study design | Participants |
N
| Intervention group (N) | Comparison group (N) | Outcomes | Follow-up time after the first treatment (months) |
---|---|---|---|---|---|---|---|
Li YY, 2017 [17] | RCT | wet AMD | 54 | Conbercept (27) | Conservative treatment (27) | ②④ | 6 |
Mei HY, 2017 [18] | RCT | wet AMD | 66 | Conbercept (33) | Conservative treatment (33) | ② | NA |
Song W, 2016 [19] | RCT | wet AMD | 112 | Conbercept (56) | Conservative treatment (56) | ②④ | 6 |
Liu ZN, 2016 [20] | RCT | wet AMD | 40 | Conbercept (20) | Ranibizumab (20) | ② | 12 |
Zhang HX, 2016 [21] | RCT | wet AMD | 50 | Conbercept (25) | Ranibizumab (25) | ②③④ | 1 |
Liu R, 2015 [22] | RCT | wet AMD | 60 | Conbercept (30) | Ranibizumab (30) | ②③ | 3 |
Wang NF, 2017 [23] | RCT | wet AMD | 76 | Conbercept (38) | Ranibizumab (38) | ①② | 3 |
Lyu P, 2016 [24] | RCT | wet AMD | 84 | Conbercept (42) | Ranibizumab (42) | ①②④ | 3 |
Zheng MW, 2017 [25] | RCT | wet AMD | 85 | Conbercept (42) | Ranibizumab (43) | ①② | 3 |
Wang XX, 2015 [26] | RCT | wet AMD | 60 | Conbercept (30) | Transpupillary thermotherapy (30) | ② | 6 |
Qin MM, 2016 [27] | RCT | wet AMD | 82 | Conbercept (41) | Transpupillary thermotherapy (41) | ② | 3 |
Li L, 2017 [28] | RCT | wet AMD | 86 | Conbercept (43) | Transpupillary thermotherapy (43) | ②④ | 6 |
Zhang X, 2015 [29] | RCT | wet AMD | 98 | Conbercept (49) | Transpupillary thermotherapy (49) | ② | 6 |
Zhu Y, 2017 [30] | RCT | wet AMD | 50 | Conbercept (25) | Triamcinolone acetonide (25) | ①②④ | 3 |
He XT, 2015 [31] | RCT | wet AMD | 60 | Conbercept (30) | Triamcinolone acetonide (30) | ①②④ | 3 |
Han X, 2017 [32] | RCT | wet AMD | 70 | Conbercept (35) | Triamcinolone acetonide (35) | ①②④ | 3 |
Pan XL, 2017 [33] | RCT | wet AMD | 76 | Conbercept (38, 42eyes) | Triamcinolone acetonide (38, 38eyes) | ② | 12 |
Yue JL, 2017 [34] | RCT | wet AMD | 76 | Conbercept (38) | Triamcinolone acetonide (38) | ② | 12 |
Study ID | Therapeutic regimen of intervention group | Therapeutic regimen of comparison group | Gender(male/female): intervention group vs comparison group | Age(years): intervention group vs comparison group | Course of disease: intervention group vs comparison group |
---|---|---|---|---|---|
Li YY, 2017 [17] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Conservative treatment | 16/11 vs 14/13 | 76.8 ± 12.6(58–85) vs 77.6 ± 11.9(59–83) | NA |
Mei HY, 2017 [18] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Conservative treatment | 17/16 vs 16/17 | 69.4 ± 4.3(63–72) vs 69.5 ± 4.1(63–71) | 3.1 ± 0.5y(2-4y) vs 3.2 ± 0.6y(2-5y) |
Song W, 2016 [19] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Conservative treatment | 30/26 vs 29/27 | 62.36 ± 6.56(53–81) vs 63.29 ± 6.45(54–82) | NA |
Liu ZN, 2016 [20] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | 11/9 vs 12/8 | 65.41 ± 6.37(57–86) vs 65.36 ± 6.74(56–85) | 3.81 ± 1.10y(6 m-10y) vs 3.88 ± 1.20y(7 m-11y) |
Zhang HX, 2016 [21] | Conbercept, NA | Ranibizumab, NA | 12/13 vs 13/12 | 68.79 ± 7.21(54–81) vs 69.03 ± 7.01(53–82) | 6.13 ± 4.27 m(7d-14 m) vs 6.25 ± 4.45 m(3d-15 m) |
Liu R, 2015 [22] | Conbercept, 1.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | NA | 65.5 ± 8.1(53–83) vs 65.2 ± 8.3(54–81) | 18.8 ± 4.1 m(8-31 m) vs 19.0 ± 4.2 m (9-32 m) |
Wang NF, 2017 [23] | Conbercept, 0.5 mg, intravitreal injection | Ranibizumab, 0.5 mg, intravitreal injection | 19/19 vs 20/18 | 62.89 ± 5.46(51–75) vs 62.85 ± 5.41(52–74) | NA |
Lyu P, 2016 [24] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | 22/20 vs 21/21 | 62.7 ± 5.3(51–73) vs 62.1 ± 4.9(49–70) | NA |
Zheng MW, 2017 [25] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Ranibizumab, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | 25/17 vs 26/17 | 65.34 ± 2.29(61–72) vs 65.13 ± 2.27(61–74) | NA |
Wang XX, 2015 [26] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | 17/13 vs 16/14 | 70.4 ± 8.4 vs 69.7 ± 8.1 | NA |
Qin MM, 2016 [27] | Conbercept, 1.0 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | 20/21 vs 22/19 | 65.8 ± 7.5(54–81) vs 64.9 ± 7.7(51–79) | 5.7 ± 4.4y(9 m-25y) vs 4.7 ± 3.2y(11 m-21y) |
Li L, 2017 [28] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | NA | 62.28 ± 3.21(52–82) vs 63.12 ± 4.36(53–83) | NA |
Zhang X, 2015 [29] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Transpupillary thermotherapy, course of treatment: 3 months | NA | 64.19 ± 4.31(54–85) vs 65.43 ± 5.76(55–86) | NA |
Zhu Y, 2017 [30] | Conbercept, NA | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | NA | NA | NA |
He XT, 2015 [31] | Conbercept, 1.0 mg, intravitreal injection. | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | 14/16 vs 13/17 | 61.52 ± 6.8(57–72) vs 61.30 ± 6.2(55–70) | NA |
Han X, 2017 [32] | Conbercept, 0.5 mg, intravitreal injection, once a month, continuous treatment for 3 months. | Triamcinolone acetonide, 0.1 ml, intravitreal injection, once a month, continuous treatment for 3 months. | 16/19 vs 14/21 | 67.54 ± 4.45(55–83) vs 68.12 ± 4.66(54–87) | 3.75 ± 0.64y(0.5-10y) vs 3.94 ± 0.71y(0.5-12y) |
Pan XL, 2017 [33] | Conbercept, 1.0 mg, intravitreal injection | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | 20/18 vs 22/16 | 71.62 ± 5.27(63–85) vs 71.59 ± 5.11(62–83) | 15.83 m ± 5.25 m(5-25 m) vs 15.65 m ± 5.34 m(7-29 m) |
Yue JL, 2017 [34] | Conbercept, 0.5 mg, intravitreal injection | Triamcinolone acetonide, 0.1 ml, intravitreal injection. | 21/17 vs 22/16 | 69.78 ± 7.52(61–82) vs 69.27 ± 8.36(60–81) | 45.62 ± 14.79 m(5-126 m) vs 46.15 ± 14.34 m(7-123 m) |